Capsida Biotherapeutics

Time away from work allows us to reduce stress, spend time with loved ones, and come back refreshed. This summer, Capsida colleagues have been taking time to relax, travel, enjoy family time, and even to get engaged! Enjoy these snapshots from our time #OutOfOffice.

HAPPY BIRTHDAY, CAPSIDA! 4 years ago this week, we officially became a company with foundational #AAV engineering technology from Viviana Gradinaru’s lab at @Caltech. Image: co-founders Nick Goeden, PhD and Nicholas Flytzanis celebrating Capsida's founding.

Capsida was honored to attend the #STXBP1 Summit+ Family Meeting this weekend. Speaking with the families of #GeneticEpilepsy patients brought home our reason for doing the work that we do. Learn more about the Family Meeting: bit.ly/3O5meyD

We're excited to share a new publication in @NatureNano describing early foundational research on an engineered, systemically delivered #AAV capsid that more effectively transduces the brain compared to #AAV9. @Caltech Read more: bit.ly/46Lc52u

🌈📸 Relive the magic of Capsida's first Pride event, Pridepalooza! 🏳️‍🌈✨ Our LGBTQ+ Employee Resource Group hosted an incredible celebration! Let this remind us of the importance of creating an inclusive workplace where everyone feels seen, heard, and celebrated. #pridemonth

Are you attending the Next-Generation Gene Therapy Vectors Summit in #Boston? We're thrilled that David Chu is presenting today on practical considerations and lessons learned from engineered vectors. Learn more about the event: bit.ly/3CSQaJk #genetherapyvectors

We're proud to share that our CEO, Peter Anastasiou, is a special guest on @biocom's new #LifeLines podcast. Tune in to hear Peter discuss next-generation gene therapies, gender parity in life science leadership, and more. Listen here: bit.ly/445A0HO

Allison Knoll, our Director of Preclinical Research, shared her experience of moving “from bench to business” at an @HBAnet Los Angeles event at Capsida headquarters. She offered attendees advice for leveraging their experience and acumen to transition from #academia to industry.

Today, Capsida's Chief Research and Innovation Officer Nicholas Flytzanis will present new preclinical data showing the potential for engineered AAV therapeutics to treat genetic #epilepsy caused by mutations in the #STXBP1 gene. Learn more: lnkd.in/gTDBTjJ5

The countdown begins! We look forward to seeing you at #ASCGT2023 this week. See our press release for details on our recent data, speaker presentations, and a panel discussion with gene therapy thought leaders: lnkd.in/gDFMd3Zz

These members of our team – and others – will be attending the American Society of Gene & Cell Therapy conference. We’d love to see you at our Industry-Sponsored Symposium, Unlocking the Potential of Gene Therapy: A Targeted Next Generation Platform, May 19 at noon. @ASGCTherapy

Thanks to all the Capsida colleagues who put their wealth of 🎸🎹🎵 knowledge to the test at our recent music trivia night! Who knew gene therapy brilliance went hand-in-hand with an encyclopedic knowledge of discography? #MusicTrivia

Happy #AdministrativeProfessionalsDay to all the hardworking administrative professionals out there, and especially our own, Beth Roder. As our Executive Assistant at Capsida, Beth is instrumental in keeping every aspect of our company running smoothly.

There are still spots left at next week's @LABioSpace Networking Mixer, organized by Biotech Connection Los Angeles (@Team_BCLA) and LA BioSpace. Capsida is excited to support this local event! RSVP here: bit.ly/41mk6rV

Seize the opportunity to be a part of the most exciting gene therapy company in the industry! If you'll be at the American Society of Gene & Cell Therapy annual meeting, stop by our career fair booth. @ASGCTherapy See where we'll be at #ASGCT2023: bit.ly/3GyOHKr

Congratulations to Nick Goeden, PhD and Viviana Gradinaru, PhD on their recent publication in Current Research in Neurobiology. Read “Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system" bit.ly/41yesCJ

Will you be at the @ASGCTherapy annual meeting in May? If so, you don’t want to miss our industry symposium featuring four luminaries in the gene therapy space! Learn more, and see where else we’ll be at ASGCT: bit.ly/3GyOHKr

It's the final day of #IWD2023 - but per these important words from our CEO Peter Anastasiou, we'll continue to stress the importance of diverse leadership in the life sciences and beyond. bit.ly/3lY2V0e

We’re pleased to announce Peter Anastasiou’s participation in a panel at the BMO Biopharma Spotlight Series – “Novel Technologies for the Delivery of Genetic Medicines.” The virtual panel, featuring Peter and other gene therapy leaders, will take place on March 28 at 10 am ET.

We’re thrilled to announce that Nicole Breese, Executive Director, Program Management at Capsida, was named a 2023 #RisingStar by the Healthcare Businesswomen’s Association. Please join us in congratulating Nicole on this honor! #HBAwoty #HBAimpact